EUCTR2015-005212-14-ES进行中（未招募）1 期
A phase IIIB, 24-week randomised, double-blind study to compare 'closed' triple therapy (FF/UMEC/VI) with 'open' triple therapy (FF/VI + UMEC), in subjects with chronic obstructive pulmonary disease (COPD) - 200812
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 1,020
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. Informed Consent: A signed and dated written informed consent prior to study participation.
- •2. Type of subject: Outpatient.
- •3. Age: Subjects 40 years of age or older at Screening (V1).
- •4. Gender: Male or female subjects.
- •A female subject is eligible to participate if she is not pregnant (as confirmed by a negative urine human chorionic gonadotrophin (hCG) test), not lactating, and at least one of the following conditions applies:
- •a. Non-reproductive potential defined as:
- •- Pre-menopausal females with one of the following:
- •- Documented tubal ligation
- •- Documented hysteroscopic tubal occlusion procedure with follow-up confirmation of bilateral tubal occlusion
- •- Hysterectomy
- •- Documented Bilateral Oophorectomy
- •- Postmenopausal defined as 12 months of spontaneous amenorrhea [in questionable cases a blood sample with simultaneous follicle stimulating hormone (FSH) and estradiol levels consistent with menopause (refer to laboratory reference ranges for confirmatory levels)]. Females on hormone replacement therapy (HRT) and whose menopausal status is in doubt will be required to use one of the highly effective contraception methods if they wish to continue their HRT during the study. Otherwise, they must discontinue HRT to allow confirmation of post-menopausal status prior to study enrolment.
- •b. Reproductive potential and agrees to follow one of the options listed in the Modified List of Highly Effective Methods for Avoiding Pregnancy in Females of Reproductive Potential (FRP) (see Appendix 5) from 30 days prior to the first dose of study treatmentand until after the last dose of study treatmentand completion of the follow-up visit.
- •The investigator is responsible for ensuring that subjects understand how to properly use these methods of contraception.
- •5. COPD Diagnosis: An established clinical history of COPD in accordance with the definition by the American Thoracic Society/European Respiratory Society [Celli, 2004].
- •6. Smoking History: Current or former cigarette smokers with a history of cigarette smoking of ?10 pack-years at Screening (V1) [number of pack years = (number of cigarettes per day/20) x number of years smoked (e.g., 20 cigarettes per day for 10 years, or 10 cigarettes per day for 20 years)]. Previous smokers are defined as those who have stopped smoking for at least 6 months prior to Screening (V1).
- •- Pipe and/or cigar use cannot be used to calculate pack-year history.
- •7. Severity of COPD symptoms: A score of ?10 on the COPD Assessment Test (CAT) at Screening (V1).
- •8. Severity of COPD Disease: A post-albuterol/salbutamol FEV1/FVC ratio of <0.70 at Screening (V1).
- •9. Existing COPD maintenance treatment: Subject must be receiving daily maintenance treatment for their COPD for at least 3 months prior to Screening (V1).
- •- Subjects receiving only PRN COPD medications are not eligible.
- •10. History of Exacerbations: Subjects must demonstrate:
- •a post-bronchodilator FEV1 < 50% predicted normal at Screening (V1) and a documented history of ? 1 moderate or severe COPD exacerbation in the 12 months prior to Screening
- •a post-bronchodilator 50% ?FEV1 < 80% predicted normal at Screening (V1) and a documented history of ? 2 moderate exacerbations or a documented history of ?1 severe COPD exacerbation (hospitalised) in the 12 months prior to Screening (V1).
- •- Percent predicted will be calculated using the European Respiratory Society Global Lung Function Init
排除标准
- •1. Pregnancy: Women who are pregnant or lactating or are planning on becoming pregnant during the study.
- •2. Asthma: Subjects with a current diagnosis of asthma. (Subjects with a prior history of asthma are eligible if they have a current diagnosis of COPD, which is the primary cause of their respiratory symptoms).
- •3. alfa-1-antitrypsin deficiency: Subjects with alfa-1-antitrypsin deficiency as the underlying cause of COPD.
- •4. Other respiratory disorders: Subjects with active tuberculosis are excluded. Subjects with other respiratory disorders are excluded if these conditions are the primary cause of their respiratory symptoms.
- •5. Lung resection: Subjects with lung volume reduction surgery (including procedures such as endobronchial valves) within the 12 months prior to Screening (V1).
- •6. Risk Factors for Pneumonia: immune suppression (e.g. advanced HIV with high viral load and low CD4 count, Lupus on immunosuppressants that would increase risk of pneumonia) or other risk factors for pneumonia.
- •7. Pneumonia and/or moderate or severe COPD exacerbation that has not resolved at least 14 days prior to Screening (V1) and at least 30 days following the last dose of oral/systemic corticosteroids (if applicable).
- •8. Other Respiratory tract infections that have not resolved at least 7 days prior to Screening (V1).
- •9. Abnormal Chest x-ray: Chest x-ray reveals evidence of pneumonia or a clinically significant abnormality not believed to be due to the presence of COPD, or another condition that would hinder the ability to detect an infiltrate on chest x-ray.
- •10. Other diseases/abnormalities: Subjects with historical or current evidence of clinically significant cardiovascular, neurological, psychiatric, renal, hepatic, immunological, gastrointestinal, urogenital, nervous system, musculoskeletal, skin, sensory, endocrine (including uncontrolled diabetes or thyroid disease) or haematological abnormalities that are uncontrolled.
- •11. Unstable liver disease: ALT >2xULN; and bilirubin >1.5xULN (isolated bilirubin >1.5xULN is acceptable if bilirubin is fractionated and direct bilirubin <35%). Current active liver or biliary disease.
- •12. Unstable or life threatening cardiac disease: subjects with any of the following at Screening (V1) would be excluded:
- •- Myocardial infarction or unstable angina in the last 6 months
- •- Unstable or life threatening cardiac arrhythmia requiring intervention in the last 3 months
- •- NYHA Class IV Heart failure
- •13. Abnormal and clinically significant 12-Lead ECG finding: An abnormal and clinically significant finding that would preclude a subject from entering the trial is defined as a 12-lead tracing that is interpreted as, but not limited to, any of the following:
- •- AF with rapid ventricular rate >120 BPM;
- •- sustained or nonsustained VT;
- •- Second degree heart block Mobitz type II and third degree heart block (unless pacemaker or defibrillator had been inserted)
- •14. Contraindications: A history of allergy or hypersensitivity to any corticosteroid, anticholinergic/muscarinic receptor antagonist, beta2-agonist, lactose/milk protein or magnesium stearate or a medical condition such as narrow-angle glaucoma, prostatic hypertrophy or bladder neck obstruction that, in the opinion of the investigator contraindicates study participation.
- •15. Cancer: Subjects with carcinoma that has not been in complete remission for at least 3 years. Subjects who have had carcinoma in situ of the cervix, squamous cell carci
研究者
相似试验
进行中（未招募）
1 期
A 24 week study comparing closed triple therapy delivered as FF/UMEC/VI vs open triple therapy delivered as FF/VI + UMEC in COPD patients.EUCTR2015-005212-14-ROGlaxoSmithKline Research & Development Ltd1,311
进行中（未招募）
1 期
A phase IIIB, 24-week randomised, double-blind study to compare ‘closed’ triple therapy (FF/UMEC/VI) with 'open' triple therapy (FF/VI + UMEC), in subjects with chronic obstructive pulmonary disease (COPD) - 200812EUCTR2015-005212-14-ITGLAXOSMITHKLINE RESEARCH AND DEVELOPMENT1,311
进行中（未招募）
1 期
A 24 week study comparing closed triple therapy delivered as FF/UMEC/VI vs open triple therapy delivered as FF/VI + UMEC in COPD patients.in subjects with chronic obstructive pulmonary disease (COPD)MedDRA version: 19.0Level: LLTClassification code 10010952Term: COPDSystem Organ Class: 100000004855EUCTR2015-005212-14-FRGlaxoSmithKline Research & Development Ltd1,020
进行中（未招募）
不适用
A randomised double-blind controlled phase III study to compare the efficacy and safety of intravenous ferric carboxymaltose (Ferinject®) with placebo in patients with chronic heart failure and iron deficiency. - FAIR-HF (Ferinject® Assessment in patients with IRon deficiency and chronic Heart Failure)iron deficiency in patients with chronic heart failureMedDRA version: 8.1Level: PTClassification code 10022970Term: Iron deficiencyEUCTR2006-004608-37-BEVifor (International) Inc576
进行中（未招募）
1 期
A randomised double-blind controlled phase III study to compare the efficacy and safety of intravenous ferric carboxymaltose (Ferinject®) with placebo in patients with chronic heart failure and iron deficiency. - FAIR-HF (Ferinject® Assessment in patients with IRon deficiency and chronic Heart Failure)iron deficiency in patients with chronic heart failureMedDRA version: 8.1Level: PTClassification code 10022970Term: Iron deficiencyEUCTR2006-004608-37-GRVifor (International) Inc576